Last reviewed · How we verify
iloprost nebuliser solution
Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.
Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation. Used for Pulmonary arterial hypertension.
At a glance
| Generic name | iloprost nebuliser solution |
|---|---|
| Also known as | Ventavis |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Prostacyclin analogue |
| Target | Prostacyclin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Iloprost works by binding to and activating the prostacyclin receptor, leading to relaxation of vascular smooth muscle and inhibition of platelet aggregation. This results in vasodilation and improved blood flow to the lungs, which is beneficial for patients with pulmonary arterial hypertension.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Headache
- Dizziness
- Nausea
- Flushing
- Palpitations
Key clinical trials
- Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery (NA)
- Iloprost for Bridging to Heart Transplantation in PH (PHASE2)
- Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (PHASE1, PHASE2)
- Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
- Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD) (PHASE3)
- Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects (PHASE4)
- Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: